• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpaceCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech

Latest content

ShowingAll content types

GreenMobility: H1-2026 Full report confirms preliminary figures, balance sheet and cash flow underline earnings quality

Analyst Comment 2026-07-09 08:00 by Michael Friis
GreenMobility

GreenMobility: Lowers revenue guidance but keeps EBITDA growth intact

Analyst Comment 2026-07-07 07:48 by Michael Friis
GreenMobility

Ascelia Pharma: CRL reshapes the investment case materially, key questions remain open

Analyst Comment 2026-07-03 16:11 by Michael Friis
Ascelia Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Curasight: Extends runway into 2027 with capital raise

Analyst Comment 2026-06-23 08:07 by Michael Friis
Curasight

MPC Energy Solutions: Guatemala clears its final hurdle, but COD slips into Q3 with a further cash bridge required

Analyst Comment 2026-06-15 11:41 by Michael Friis
MPC Energy Solutions

Curasight: Encouraging preliminary uTREAT® readout de-risks the first of four H2 catalysts

Analyst Comment 2026-06-08 07:22 by Michael Friis
Curasight

Curasight (Investment Case): Four high-value read-outs on track for H2 2026

Research 2026-06-02 12:00 by Michael Friis, Victor Skriver
Curasight

GreenMobility: Launches share buyback programme of up to DKK 6 million

Analyst Comment 2026-06-01 07:30 by Michael Friis
GreenMobility

ExpreS2ion (Investment Case): Q1 2026 - continued progress across pipeline and partner programmes

Research 2026-05-29 08:00 by Michael Friis, Victor Skriver
ExpreS2ion Biotech

ExpreS2ion: Presentation of Q1 2026 report (Recording)

Analyst Comment 2026-05-28 13:02 by Michael Friis
ExpreS2ion Biotech